关键词: 癌，非小细胞肺癌；癌胚抗原；角蛋白

Abstract:

Ojective   To investigate the roles of PET/CT, carcinoembryonic antigen(CEA) and soluble cytokeratin 19 fragment(CYFRA21-1) in predicting the therapeutic effect of Targeted drug on nonsmall cell lung cancer (NSCLC). Methods   Before treated with the targeted drug, 39 patients were determined EGFR mutation the standard uptake value(SUV) of PET/CT and serum levels of CEA and CYFRA21-1, and decreased degrees of these indexes were determined after two weeks of treatment. Then relations of these indexes with progression-free survival (PFS) and overall survival (OS) were analyzed. Results   Patients with SUV≤5 could achieve longer PFS and OS, so could those with a reduction ≥50% in the CEA level after two weeks of treatment. However, patients with a reduction ≥50% in the CYFRA21-1 level could not achieve longer PFS and OS. Those patients with EGFR mutation had lower SUV than those with wild type EGFR(P<0.05). After two weeks of treatment, the ratio of patients with the CEA level reduced by ≥50% was higher  in patients with EGFR mutation than in those with wild type(P<0.05). The binary logistic analysis result showed that SUV≤5 was an independent prognostic factor for EGFR mutation (P<0.001). Conclusion   The SUV of PET-CT and change of the CEA level in the early treatment could predict the therapeutic effect of targeted drug on NSCLC.

Key words: Carcinoma, non-small-cell lung; Carcinoembryonic antigen； Keratin